This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass (NCT00489424), a randomized phase 4 study. The primary outcome is Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication..
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT00489424 |
| Phase | Phase 4 |
| Condition | Osteoporosis |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Enrollment | 793 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Novartis Pharmaceuticals |
| Results posted | Yes |
2. Clinical Question
Population
Post-menopausal women with low bone mass. The primary endpoint population is described as the Intent to Treat (ITT) population. The registry lists osteoporosis as a condition, but does not give further eligibility criteria in the record.
Intervention
Acetaminophen or fluvastatin given around an intravenous infusion of a single dose of zoledronic acid 5 mg. The study description focuses on post-dose symptoms during the 3-day period after infusion. The acetaminophen regimen is described as capsules given before infusion and repeatedly over the next 3 days; the record’s full dosing description for the other regimens is not available in its entirety.
Comparator
Placebo, with a double-dummy design using matching placebos for the active treatments. The study is described as randomized, multicenter, double-blind, and parallel-group.
Primary question
Among participants in the ITT population, what proportion had either a clinically significant increase in oral body temperature or used ibuprofen at least once during the 0 - 3 days after zoledronic acid infusion? The registry defines the temperature criterion using an increase from baseline and a mean oral reading threshold. It does not report the observed proportions or a comparison between groups.
In practical terms, the study question combines a measured temperature event with use of rescue medication. The comparison of interest is whether the proportion meeting either part of that definition differed across the acetaminophen, fluvastatin, and placebo groups. The registry record describes this as an evaluation of the rate and severity of post-dose symptoms after infusion; it does not establish, in the posted results, whether either active treatment changed the primary endpoint.
3. Trial Design
The registry describes a randomized, multicenter, double-blind, double-dummy, parallel-group Phase 4 study. The groups were acetaminophen, fluvastatin, and placebo. The record gives an enrollment of 793. It lists the study as completed, with a start in 2007-06 and primary completion in 2007-12. Novartis Pharmaceuticals is listed as the sponsor.
All groups were studied in the context of a single intravenous infusion of zoledronic acid 5 mg. The acetaminophen and fluvastatin regimens were compared with placebo for post-dose symptoms. The double-dummy description indicates that matching placebos were used alongside the active treatments, supporting masking across groups when the regimens differed. The official study title also describes the study as double-blind and parallel-group.
Random allocation is intended, in general, to reduce systematic differences between groups at the point of assignment. A parallel-group design assigns participants to a study group for comparison rather than comparing each participant with themselves under multiple assigned treatments. These general design features can strengthen a group comparison, but they do not establish that groups were similar in every characteristic or that all randomized participants contributed endpoint data.
The primary endpoint is defined for the ITT population and covers the 0 - 3 days after infusion. The record also lists outcomes concerning temperature, rescue medication use, symptom severity, and a visual analog scale. It does not report the randomization procedure, allocation concealment details, masking assessment, adherence, withdrawals by group, or the statistical plan. Those design details are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| STARTED | 267 | 264 | 262 |
| COMPLETED | 263 | 259 | 257 |
| NOT COMPLETED | 4 | 5 | 5 |
Reasons for not completing this period:
| Reason | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|
| Adverse Event | 3 | 3 | 4 |
| Lack of Efficacy | 1 | 0 | 0 |
| Administrative problems | 0 | 2 | 1 |
Analysis population for the primary outcome, as defined in the registry: Intent to Treat (ITT) population.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Placebo | Acetaminophen | Fluvastatin | Total |
|---|---|---|---|---|---|
| Participants analysed | 267 | 264 | 262 | 793 | |
| Age, Customized: Between 45 and 55 years | participants | 64 | 69 | 67 | 200 |
| Age, Customized: Between 56 and 64 years | participants | 102 | 98 | 92 | 292 |
| Age, Customized: >=65 years | participants | 101 | 97 | 103 | 301 |
| Sex/Gender, Customized: Female | participants | 267 | 264 | 262 | 793 |
6. Primary Endpoint
The registry lists the primary outcome as Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication., measured over 0 - 3 days.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | proportion of patients |
| Endpoint classification | Binary Endpoint |
The primary endpoint is the proportion of patients with either a clinically significant increase in oral body temperature or use of rescue medication. Its timeframe is 0 - 3 days after zoledronic acid infusion, and its stated population is the ITT population. Rescue medication is specified as ibuprofen used at least once during the 3-day period. The temperature event requires an increase of at least 1 degree Celsius from baseline and a mean oral body temperature reading of at least 38.5 degrees Celsius, occurring at least once during the treatment period.
This is a composite endpoint: a participant meets it by satisfying either the temperature criterion or the rescue-medication criterion. General statistical context: a composite can capture more than one way an event of interest may occur, but its overall result does not by itself reveal which component contributed most. The component outcomes therefore matter when interpreting what drives any group difference. The registry lists related secondary outcomes, including temperature increase and rescue medication use separately, but does not report their results.
The registry record does not give the primary endpoint counts, proportions, effect estimate, confidence interval, or statistical test result. Consequently, the endpoint definition is available, but the size and precision of any treatment-group comparison are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies the intended primary comparison and defines the event, population, and timeframe. It does not report the observed primary endpoint results. No group-specific proportions, between-group effect estimate, confidence interval, or p-value are available in the record. The posted information therefore does not show whether the endpoint occurred more or less often in any study group, nor how precisely a difference was estimated.
This distinction matters because a trial design and endpoint definition describe what researchers planned to compare, while outcome data are needed to describe what was observed. The record lists enrollment of 793 and the groups, but enrollment alone cannot establish the primary endpoint frequency or the result of the comparison. It would be inappropriate to infer an effect from the study title, the stated purpose, or the fact that the study is completed.
The endpoint combines a temperature criterion and rescue medication use. General statistical context: when a composite outcome is used, the overall result can reflect either component or both. Separate component results help clarify whether an observed group pattern is associated with temperature, medication use, or a combination. Although the registry lists secondary measures related to these components, it does not report their numerical findings.
Uncertainty is also central to interpretation. General statistical context: a confidence interval describes a range of values compatible with the data and the statistical method used; a wider interval indicates less precision than a narrower one. Since no primary endpoint interval is reported, the precision of the treatment comparison cannot be assessed from the registry record. No reported p-value is available to characterize statistical evidence under a specified test, and a p-value, even if reported, would not by itself describe the size or practical meaning of an effect.
The record reports adverse-event counts, but those are safety summaries, not substitutes for the primary endpoint analysis. Safety counts address different outcomes and should not be used to infer the frequency of post-dose symptoms as defined by the primary endpoint. Likewise, the listed serious adverse event terms do not establish the primary endpoint result.
In summary, the registry makes the question and endpoint definition clear, but does not provide the primary outcome evidence needed to answer that question. Any conclusion about the direction, magnitude, or precision of a group difference is not reported in the registry record. The trial’s stated objective should not be mistaken for an observed finding.
9. Statistical Methods Explained
The primary endpoint is expressed as a proportion of participants with an event. General statistical context: for a binary outcome, each participant is classified according to whether the event definition was met during the specified period. The group proportion is then the number meeting the definition relative to the relevant analysis population. The registry supplies the outcome definition and ITT population, but not the group counts or proportions for this endpoint.
The word composite is important. A participant qualifies through either a clinically significant temperature increase or at least one use of rescue ibuprofen. General statistical context: an “or” rule makes the composite event occur if any listed component occurs. A composite can be useful when several related manifestations are of interest, but it can combine components that differ in frequency, importance, or measurement. Component-level results and clear definitions help readers understand what an overall comparison represents. Component results are not reported in the registry record.
For a binary outcome, common effect summaries include a difference between group proportions, a ratio of proportions, or an odds ratio. General statistical context: these summaries describe different aspects of a comparison and are not interchangeable. Their interpretation depends on the chosen measure and on the event frequencies. No such primary endpoint effect estimate is reported, so there is no numerical estimate to interpret or compare across scales.
A confidence interval is a way to express the uncertainty around an estimate under a specified statistical procedure. General statistical context: it conveys a range of estimates compatible with the observed data and assumptions; it is not a guarantee that the true effect lies in that particular interval. The interval’s width is informative about precision, while its position relative to a null value may be relevant to a hypothesis test. No confidence interval for the primary endpoint is reported in the registry record.
A p-value, in general, describes how compatible data are with a null hypothesis under the assumptions of a particular statistical model. It is not the probability that the null hypothesis is true, and it does not measure the size or importance of an effect. The registry record does not report a primary endpoint p-value or identify a test used for that endpoint. It also does not report whether analyses were adjusted for baseline factors or how any model assumptions were assessed.
Randomization supports a comparison by assigning treatment groups through a chance-based process, reducing the likelihood that allocation is systematically determined by participant characteristics. General statistical context: randomization does not eliminate chance imbalances, prevent missing outcomes, or guarantee adherence to assigned treatment. The registry describes the study as randomized but does not report the randomization sequence generation or concealment procedures.
The study is described as double-blind and double-dummy. General statistical context: masking can reduce the influence of treatment knowledge on participant reports, care decisions, or outcome assessment. A double-dummy approach uses matching placebo regimens where active regimens differ, helping maintain masking across groups. The registry provides the design description but does not report whether masking was assessed or maintained throughout follow-up.
For a binary endpoint, sample-size planning generally depends on the assumed event frequency, the effect the study is designed to detect, the type I error level, allocation, and the desired statistical power. General statistical context: power is a planning property under specified assumptions, not a description of the probability that a completed study has demonstrated an effect. The registry record gives sample-size planning assumptions of a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation for an effect expressed as a stated fraction of the observed effect. It does not report a numerical planning illustration in the registry record, and such an illustration should not be treated as observed power.
The stated planning assumptions concern a two-arm comparison, whereas the study description lists three groups. That distinction means the assumptions alone do not document how every possible pairwise or multi-group comparison was planned. The registry record does not report the primary comparison specification, any multiplicity adjustment, the planned analysis model, or a statistical analysis plan. There is also no primary outcome analysis listed in the registry record. Without those details and the outcome estimates, a statistical re-analysis or assessment of the reported testing strategy is not possible.
Over-dispersion is generally relevant when count data vary more than a simple model expects. General statistical context: allowing for extra variability can prevent standard errors from being understated when the model’s assumptions are otherwise too restrictive. The primary endpoint is a binary participant-level proportion, not a count-rate outcome as described in the record, so over-dispersion is not a reported feature of its analysis. No analysis model is reported that would permit evaluating model fit or variance assumptions.
Finally, endpoint measurement depends on consistent application of the temperature rule and recording of rescue medication use. General statistical context: outcome misclassification can affect group comparisons, particularly if measurement practices differ between groups. The registry gives operational criteria for the temperature event and identifies rescue medication, but does not report measurement procedures, completeness of diaries or records, or adjudication processes. These details are not reported in the registry record.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists a primary endpoint and several secondary outcomes. The secondary outcomes cover clinically significant oral temperature increase, rescue medication use and tablet count, time to first rescue medication, questionnaire symptom severity, severe questionnaire symptoms, and change in visual analog scale symptom severity. The record lists 8 outcome measures, but does not report the analysis results for them.
General statistical context: when many outcomes or group comparisons are tested, the chance of at least one apparently unusual result can increase. A prespecified hierarchy, adjustment procedure, or clear distinction between primary and exploratory analyses can help readers understand how multiple findings were handled. The registry record does not report a multiplicity strategy, outcome hierarchy beyond identifying the primary endpoint, or which comparisons were planned.
The primary endpoint population is described as ITT. General statistical context: an ITT analysis aims to analyze participants according to their randomized group, regardless of treatment adherence, but the label alone does not show how missing outcomes were handled or which participants were included in the calculation. The registry record does not report missing primary endpoint data, the extent of loss to follow-up, imputation methods, or sensitivity analyses.
The record does not report an interim analysis plan, stopping rules, or the statistical analysis plan. These details are not reported in the registry record. Without them, the handling of missingness and multiplicity cannot be evaluated from the posted information.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Placebo | 1 | 267 | 0.4% |
| Acetaminophen | 2 | 264 | 0.8% |
| Fluvastatin | 2 | 262 | 0.8% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Placebo | 34 of 267 |
| Acetaminophen | 39 of 264 |
| Fluvastatin | 36 of 262 |
Most frequent serious adverse event terms
| Event term | Organ system | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|---|
| Uveitis | Eye disorders | 0 of 267 | 0 of 264 | 1 of 262 |
| Pyrexia | General disorders | 0 of 267 | 0 of 264 | 1 of 262 |
| Hypokalaemia | Metabolism and nutrition disorders | 1 of 267 | 0 of 264 | 0 of 262 |
| Convulsion | Nervous system disorders | 0 of 267 | 0 of 264 | 1 of 262 |
| Syncope | Nervous system disorders | 0 of 267 | 1 of 264 | 0 of 262 |
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | 0 of 267 | 1 of 264 | 0 of 262 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Placebo | Acetaminophen | Fluvastatin |
|---|---|---|---|---|
| Headache | Nervous system disorders | 8 of 267 | 14 of 264 | 15 of 262 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 13 of 267 | 9 of 264 | 14 of 262 |
| Myalgia | Musculoskeletal and connective tissue disorders | 14 of 267 | 11 of 264 | 10 of 262 |
| Nausea | Gastrointestinal disorders | 7 of 267 | 16 of 264 | 8 of 262 |
Serious events with the highest arm-level rate: uveitis (0.4%), pyrexia (0.4%), convulsion (0.4%), syncope (0.4%), pleuritic pain (0.4%).
The registry reports serious adverse events and other adverse events separately by group. For serious adverse events, the placebo group lists 1 affected participant among 267 at risk; the acetaminophen group lists 2 among 264 at risk; and the fluvastatin group lists 2 among 262 at risk. For other adverse events, the placebo group lists 34 among 267 at risk; the acetaminophen group lists 39 among 264 at risk; and the fluvastatin group lists 36 among 262 at risk.
These are counts of participants reported as affected and participants at risk, not the primary endpoint results. They should be read as registry safety summaries and not as evidence about the frequency of the temperature-or-rescue-medication composite. The record lists uveitis, pyrexia, convulsion, syncope, pleuritic pain, and hypokalaemia among the top serious event terms, each shown as 0.4%. The record does not assign those listed terms to a particular study group in the available summary.
General statistical context: small differences in event counts do not alone establish a treatment-related difference. Interpretation depends on event definitions, follow-up, completeness of reporting, and an appropriate comparative analysis. Deaths are not reported in the registry record.
12. What the Result Does, and Does Not, Mean
The registry record describes a trial designed to compare acetaminophen and fluvastatin with placebo for symptoms during the period after a zoledronic acid infusion. It identifies the population, study groups, design, and composite primary endpoint. These registry entries clarify what the researchers set out to study, but they are not a report of the primary outcome findings.
The primary endpoint was defined as a clinically significant oral temperature increase or use of ibuprofen at least once during the 0 - 3 days after infusion. Because the endpoint combines these components, an overall result would need interpretation alongside the component results. The registry lists related secondary outcomes, but no primary or secondary numerical results are reported in the record.
Accordingly, the posted information does not establish whether the endpoint was more common in one group, the size of any difference, or how precise a comparison would be. It also does not support a conclusion about the effect of either active treatment on post-dose symptoms. A completed study and a stated objective do not substitute for reported outcome data.
General statistical context: even when a group comparison is available, statistical evidence and clinical meaning are separate considerations. An effect estimate describes the observed contrast, while its uncertainty indicates how precisely that contrast is estimated. Interpretation also depends on the outcome definition, the analysis population, missing data, and the credibility of the comparison. Those elements cannot be fully assessed for the primary endpoint from the registry record because its results and analysis details are not reported.
The safety summaries provide separate adverse-event counts. They do not answer the primary question, and the event counts should not be treated as proof for or against a difference in the composite endpoint. The record is therefore informative about the trial’s design and intended measurement, but it does not provide enough reported outcome information to characterize the trial’s primary comparative result.
13. Why This Trial Matters Statistically
This trial is statistically notable for its composite endpoint and double-dummy comparison. The primary endpoint combines a temperature-based criterion with rescue medication use, capturing more than one form of post-dose event within a defined timeframe. That construction raises familiar questions about how components are combined and whether each component contributes similarly to the overall result. The registry defines the composite but does not report component results.
The design also illustrates why a clear comparator and masking description matter. The trial is described as randomized, parallel-group, double-blind, and double-dummy, with acetaminophen and fluvastatin compared against placebo. General statistical context: randomization and masking are design features intended to support credible comparisons, but interpretation still depends on reported outcome data, analysis choices, and missing-data handling.
The registry identifies the ITT population for the primary endpoint, which is an important part of defining the target analysis. Yet an analysis-population label is not enough to evaluate the analysis without information about missing outcomes, exclusions, and the statistical method. Those details are not reported in the registry record.
Most importantly, the record distinguishes the existence of a trial from the availability of a result. It describes the planned question and reports safety counts, but no primary endpoint analysis is listed. This makes the record useful for understanding the trial’s design and measurement strategy while limiting any statistical conclusion about comparative effects. The case underscores that endpoint definitions, analysis plans, effect estimates, and uncertainty measures each serve different roles in interpreting a clinical study.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main limitation for statistical interpretation is that the registry record does not report the primary endpoint results. Without group-specific event counts or proportions, there is no reported effect estimate, confidence interval, or test result to interpret. The record also lists no analyses, so the primary comparison cannot be checked against the stated endpoint definition.
The registry identifies the ITT population, but does not report how many participants contributed primary endpoint data, how missing observations were handled, or whether any participants were excluded from the analysis. The enrollment figure cannot resolve those questions. The record also does not report adherence, withdrawals by group, or protocol deviations.
Additional analysis details are not reported in the registry record, including the statistical model, planned group contrasts, multiplicity handling, and interim analysis procedures. These omissions limit assessment of how the planned comparison was implemented and how uncertainty should be interpreted.
The composite endpoint includes both an objective temperature rule and self- or care-related rescue medication use. General statistical context: these components can be affected by different measurement processes, and an overall composite result can conceal different patterns across components. The registry does not report component findings or enough measurement detail to assess that issue.
The treatment-regimen descriptions in the registry are not complete for every group in the available record. The reported serious adverse event terms are not linked to individual groups in the summary, and deaths are not reported in the registry record. These limitations apply to interpretation of the posted registry information; they do not establish what may have been reported elsewhere.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass — NCT00489424.
- Registry record last updated 2011-02-18; status last verified 2011-02.
- Results first posted 2009-09-14.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry describes NCT00489424 as a completed Phase 4 randomized, multicenter, double-blind, double-dummy, parallel-group study sponsored by Novartis Pharmaceuticals. It enrolled 793 participants and compared acetaminophen and fluvastatin with placebo in post-menopausal women with low bone mass receiving zoledronic acid 5 mg by intravenous infusion.
The primary endpoint was the proportion of participants in the ITT population with a clinically significant increase in oral body temperature or use of ibuprofen during the 0 - 3 days after infusion. The record lists secondary outcomes related to temperature, rescue medication, and symptom severity. It reports group-specific serious and other adverse-event counts, but no primary endpoint analysis or numerical outcome result. Statistical analysis details, missing-data methods, and multiplicity procedures are not reported in the registry record.